BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, Kaji M, Ohkawa M. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008;49:1245-1248. [PMID: 18632827 DOI: 10.2967/jnumed.108.052639] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Bertagna F, Bertoli M, Bosio G, Biasiotto G, Sadeghi R, Giubbini R, Treglia G. Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2014;8:493-500. [PMID: 26202754 DOI: 10.1007/s12072-014-9566-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
2 Zheng J, Miao W, Huang C, Lin H. Evaluation of 99mTc-3PRGD2 integrin receptor imaging in hepatocellular carcinoma tumour-bearing mice: comparison with 18F-FDG metabolic imaging. Ann Nucl Med 2017;31:486-94. [PMID: 28474165 DOI: 10.1007/s12149-017-1173-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Dunphy MP, Lewis JS. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 2009;50 Suppl 1:106S-21S. [PMID: 19380404 DOI: 10.2967/jnumed.108.057281] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
4 Li YC, Yang CS, Zhou WL, Li HS, Han YJ, Wang QS, Wu HB. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. World J Gastroenterol. 2018;24:494-503. [PMID: 29398870 DOI: 10.3748/wjg.v24.i4.494] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
5 Nguyen BD, Heller MT, Roarke MC. Nodular Fat-Sparing Hepatic Parenchyma as 11C-Choline-Avid Finding on PET/CT. Clin Nucl Med 2020;45:228-9. [PMID: 31977460 DOI: 10.1097/RLU.0000000000002898] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Roivainen A, Naum A, Nuutinen H, Leino R, Nurmi H, Någren K, Parkkola R, Virtanen J, Kallajoki M, Kujari H, Ovaska J, Roberts P, Seppänen M. Characterization of hepatic tumors using [11C]metomidate through positron emission tomography: comparison with [11C]acetate. EJNMMI Res 2013;3:13. [PMID: 23442595 DOI: 10.1186/2191-219X-3-13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with 18F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging 2010;37:2188-93. [DOI: 10.1007/s00259-010-1496-z] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
8 Wu HB, Wang QS, Zhong JM, Zhou WL, Li HS, Qiao-yu W. Preliminary study on the evaluation of olfactory neuroblastoma using PET/CT. Clin Nucl Med 2011;36:894-8. [PMID: 21892040 DOI: 10.1097/RLU.0b013e31821a2711] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lodi F, Malizia C, Castellucci P, Cicoria G, Fanti S, Boschi S. Synthesis of oncological [11C]radiopharmaceuticals for clinical PET. Nucl Med Biol 2012;39:447-60. [PMID: 22172394 DOI: 10.1016/j.nucmedbio.2011.10.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
10 Wang Z, Kang F, Gao Y, Liu Y, Xu X, Ma X, Ma W, Yang W, Wang J. Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase. Mol Imaging Biol 2018;20:388-97. [DOI: 10.1007/s11307-017-1150-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol. 2015;70:128-137. [PMID: 25459673 DOI: 10.1016/j.crad.2014.09.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
12 Ahmadzadehfar H, Sabet A, Wilhelm K, Biersack HJ, Risse J. Iodine-131-lipiodol therapy in hepatic tumours. Methods. 2011;55:246-252. [PMID: 21664971 DOI: 10.1016/j.ymeth.2011.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
13 Slaets D, De Bruyne S, Dumolyn C, Moerman L, Mertens K, De Vos F. Reduced dimethylaminoethanol in [18F]fluoromethylcholine: an important step towards enhanced tumour visualization. Eur J Nucl Med Mol Imaging 2010;37:2136-45. [DOI: 10.1007/s00259-010-1508-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
14 Schobert IT, Savic LJ. Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism. Cancers (Basel) 2021;13:3645. [PMID: 34359547 DOI: 10.3390/cancers13153645] [Reference Citation Analysis]
15 Lee JM, Park KM, Lee SY, Choi J, Hwang DW, Lee YJ. Metastasis of hepatocellular carcinoma to the ovary: a case report and review of the literature. Gut Liver 2011;5:543-7. [PMID: 22195258 DOI: 10.5009/gnl.2011.5.4.543] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
16 Hayano K, Fuentes-Orrego JM, Sahani DV. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol 2014;20:3059-68. [PMID: 24696594 DOI: 10.3748/wjg.v20.i12.3059] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
17 Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol. 2011;2011:519783. [PMID: 22007313 DOI: 10.4061/2011/519783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
18 Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med. 2009;50:1441-1447. [PMID: 19690030 DOI: 10.2967/jnumed.109.065896] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
19 Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol. 2015;2:191-200. [PMID: 30190998 DOI: 10.2217/hep.15.6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
20 Vanpouille C, Le Jeune N, Kryza D, Clotagatide A, Janier M, Dubois F, Perek N. Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model. Eur J Nucl Med Mol Imaging 2009;36:1256-64. [PMID: 19300998 DOI: 10.1007/s00259-009-1101-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
21 Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, Giordano A. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012;26:451-61. [DOI: 10.1007/s12149-012-0602-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
22 Hayano K, Lee SH, Sahani DV. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 2015;25:121-8. [PMID: 25969635 DOI: 10.4103/0971-3026.155835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
23 Hodolic M. Role of (18)F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol 2011;45:17-21. [PMID: 22933929 DOI: 10.2478/v10019-010-0050-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
24 Tulin PE, Dolgushin MB, Odzharova AA, Mikhaylov AI, Medvedeva BM, Shiryaev SV, Dolgushin BI. Perfusion CT and PET with 18F-FDG and 18F-FCh in the complex diagnosis of hepatocellular carcinoma. Eur J Hybrid Imaging 2017;1:13. [PMID: 29782602 DOI: 10.1186/s41824-017-0018-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
25 Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 2012;81:2417-22. [PMID: 21899970 DOI: 10.1016/j.ejrad.2011.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
26 Zhao Y, Yao Q, Tan H, Wu B, Hu P, Wu P, Gu Y, Zhang C, Cheng D, Shi H. Design and preliminary assessment of 99mTc-labeled ultrasmall superparamagnetic iron oxide-conjugated bevacizumab for single photon emission computed tomography/magnetic resonance imaging of hepatocellular carcinoma. J Radioanal Nucl Chem 2014;299:1273-80. [DOI: 10.1007/s10967-013-2846-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
27 Sharma B, Martin A, Zerizer I. Positron Emission Tomography-Computed Tomography in Liver Imaging. Seminars in Ultrasound, CT and MRI 2013;34:66-80. [DOI: 10.1053/j.sult.2012.11.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
28 Shin D, Han S, Oh D, Im S, Kim T, Bang Y. Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol 2011;68:165-75. [DOI: 10.1007/s00280-010-1454-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
29 Zhang Z, Liu S, Ma H, Nie D, Wen F, Zhao J, Sun A, Yuan G, Su S, Xiang X, Hu P, Tang G. Validation of R-2-[18F]Fluoropropionic Acid as a Potential Tracer for PET Imaging of Liver Cancer. Mol Imaging Biol 2019;21:1127-37. [DOI: 10.1007/s11307-019-01346-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Wachsmann J, Peng F. Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. World J Gastroenterol. 2016;22:221-231. [PMID: 26755872 DOI: 10.3748/wjg.v22.i1.221] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
31 Song MJ, Bae SH, Yoo IeR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol. 2012;18:3215-3222. [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
32 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018;10:336-43. [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
33 Goh V, Sarker D, Osmany S, Cook GJ. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:1070-1079. [PMID: 22434049 DOI: 10.1007/s00259-012-2096-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
34 Veres DS, Máthé D, Futó I, Horváth I, Balázs Á, Karlinger K, Szigeti K. Quantitative Liver Lesion Volume Determination by Nanoparticle-Based SPECT. Mol Imaging Biol 2014;16:167-72. [DOI: 10.1007/s11307-013-0679-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
35 Lanza E, Donadon M, Felisaz P, Mimmo A, Chiti A, Torzilli G, Balzarini L, Lopci E. Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. Nuclear Medicine Communications 2017;38:826-36. [DOI: 10.1097/mnm.0000000000000719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
36 Wu HB, Wang QS, Wang MF, Zhen X, Zhou WL, Li HS. Preliminary study of 11C-choline PET/CT for T staging of locally advanced nasopharyngeal carcinoma: comparison with 18F-FDG PET/CT. J Nucl Med 2011;52:341-6. [PMID: 21321282 DOI: 10.2967/jnumed.110.081190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
37 Castilla-lièvre M, Franco D, Gervais P, Kuhnast B, Agostini H, Marthey L, Désarnaud S, Helal B. Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016;43:852-9. [DOI: 10.1007/s00259-015-3241-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]
38 Miao W, Nie P, Yang G, Wang Y, Yan L, Zhao Y, Yu T, Yu M, Wu F, Rao W, Wang Z. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur J Nucl Med Mol Imaging 2021. [PMID: 33813592 DOI: 10.1007/s00259-021-05328-w] [Reference Citation Analysis]
39 Lee Z. [18F]-choline PET/CT as an imaging biomarker for primary liver cancers. Transl Cancer Res 2016;5:S1489-92. [PMID: 29607294 DOI: 10.21037/tcr.2016.12.41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Nakajo M, Kajiya Y, Jinguji M, Nakabeppu Y, Nakajo M, Nihara T, Yoshiura T. Current clinical status of 18F-FLT PET or PET/CT in digestive and abdominal organ oncology. Abdom Radiol (NY) 2017;42:951-61. [PMID: 27770160 DOI: 10.1007/s00261-016-0947-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Shiomi S, Kawabe J. Clinical applications of positron emission tomography in hepatic tumors. Hepatol Res. 2011;41:611-617. [PMID: 21711419 DOI: 10.1111/j.1872-034x.2011.00819.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
42 Hwang SH, Lee JW, Cho HJ, Kim KS, Choi GH, Yun M. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:34-39. [PMID: 27775949 DOI: 10.1097/rlu.0000000000001449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Lee JW, Paeng JC, Kang KW, Kwon HW, Suh K, Chung J, Lee MC, Lee DS. Prediction of Tumor Recurrence by 18 F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma. J Nucl Med 2009;50:682-7. [DOI: 10.2967/jnumed.108.060574] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 9.8] [Reference Citation Analysis]
44 Salem N, Kuang Y, Corn D, Erokwu B, Kolthammer JA, Tian H, Wu C, Wang F, Wang Y, Lee Z. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol. 2011;13:140-151. [PMID: 20401538 DOI: 10.1007/s11307-010-0308-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
45 Wu HB, Wang QS, Li BY, Li HS, Zhou WL, Wang QY. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011;36:1092-1097. [PMID: 22064078 DOI: 10.1097/rlu.0b013e3182335df4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
46 Fartoux L, Balogova S, Nataf V, Kerrou K, Huchet V, Rosmorduc O, Talbot JN. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nucl Med Commun. 2012;33:757-765. [PMID: 22504293 DOI: 10.1097/mnm.0b013e328350fb9f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
47 Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-carrié N, Baranes L, Allaire M, Calderaro J, Azoulay D, Nahon P, Seror O, Mallat A, Soussan M, Duvoux C, Itti E, Nault JC. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. Journal of Hepatology 2018;69:336-44. [DOI: 10.1016/j.jhep.2018.02.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
48 Schmid A, Rignall B, Pichler BJ, Schwarz M. Quantitative analysis of the growth kinetics of chemically induced mouse liver tumors by magnetic resonance imaging. Toxicol Sci 2012;126:52-9. [PMID: 22273797 DOI: 10.1093/toxsci/kfs018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
49 Ahn SG, Jeon TJ, Lee SD, Kim SH, Cho HJ, Yun M, Park YN, Lee JD, Park SJ, Kim KS. A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. Eur J Surg Oncol. 2013;39:964-973. [PMID: 23859893 DOI: 10.1016/j.ejso.2013.06.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
50 Kolthammer JA, Corn DJ, Tenley N, Wu C, Tian H, Wang Y, Lee Z. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38:1248-1256. [PMID: 21344223 DOI: 10.1007/s00259-011-1743-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
51 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
52 Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One 2014;9:e105679. [PMID: 25153834 DOI: 10.1371/journal.pone.0105679] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
53 Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105-121. [PMID: 20113679 DOI: 10.1053/j.semnuclmed.2009.11.001] [Cited by in Crossref: 115] [Cited by in F6Publishing: 93] [Article Influence: 10.5] [Reference Citation Analysis]
54 Guglielmo P, Pisu N, Sanna S, Pung BLJ, Boero M. Incidental Finding on 11C-Choline-PET/CT of Hepatocellular Carcinoma Recurrence in a Prostate Cancer Patient With Negative Abdominal CT Scan. Clin Nucl Med 2020;45:703-4. [PMID: 32701803 DOI: 10.1097/RLU.0000000000003203] [Reference Citation Analysis]
55 Refaat R, Basha MAA, Hassan MS, Hussein RS, El Sammak AA, El Sammak DAEA, Radwan MHS, Awad NM, Saad El-Din SA, Elkholy E, Ibrahim DRD, Saleh SA, Montasser IF, Said H. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma. Eur Radiol. 2018;28:5356-5367. [PMID: 29948070 DOI: 10.1007/s00330-018-5425-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
56 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
57 Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol. 2013;58:169-177. [PMID: 22944253 DOI: 10.1016/j.jhep.2012.08.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
58 Levy CS, Costa FGB, Faria DP, Stefano JT, Cogliati B, Oliveira CP. 18F-FDG PET/CT as an assessment tool of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease development in experimental model.Arq Gastroenterol. 2019;56:45-50. [PMID: 31141073 DOI: 10.1590/S0004-2803.201900000-02] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Lopci E, Fanti S. Non-FDG PET/CT. Recent Results Cancer Res 2020;216:669-718. [PMID: 32594402 DOI: 10.1007/978-3-030-42618-7_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Mulé S, Chalaye J, Legou F, Tenenhaus A, Calderaro J, Galletto Pregliasco A, Laurent A, Kharrat R, Amaddeo G, Regnault H, Tacher V, Kobeiter H, Itti E, Luciani A. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. Eur Radiol 2020;30:5348-57. [PMID: 32405753 DOI: 10.1007/s00330-020-06923-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
61 Sørensen M, Frisch K, Bender D, Keiding S. The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:1723-1731. [PMID: 21553087 DOI: 10.1007/s00259-011-1831-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
62 Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation: Monitoring Patients with Hepatocellular Carcinoma. Liver Transpl 2011;17:S117-27. [DOI: 10.1002/lt.22334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
63 Filippi L, Schillaci O, Bagni O. Recent advances in PET probes for hepatocellular carcinoma characterization. Expert Review of Medical Devices 2019;16:341-50. [DOI: 10.1080/17434440.2019.1608817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
64 Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, Huchet V, Ancel D, Grange JD, Rosmorduc O. Detection of hepatocellular carcinoma with PET/CT: A prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51:1699-1706. [PMID: 20956466 DOI: 10.2967/jnumed.110.075507] [Cited by in Crossref: 129] [Cited by in F6Publishing: 97] [Article Influence: 11.7] [Reference Citation Analysis]
65 Talbot J, Michaud L, Grange J, Rosmorduc O, Balogova S. Use of choline PET for studying hepatocellular carcinoma. Clin Transl Imaging 2014;2:103-13. [DOI: 10.1007/s40336-014-0055-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Malla RR, Kumari S, Kgk D, Momin S, Nagaraju GP. Nanotheranostics: Their role in hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2020;151:102968. [DOI: 10.1016/j.critrevonc.2020.102968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
67 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 79] [Article Influence: 31.0] [Reference Citation Analysis]
68 Lopci E, Fanti S. Molecular imaging in oncology. Recent Results Cancer Res 2013;187:371-400. [PMID: 23179889 DOI: 10.1007/978-3-642-10853-2_13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
69 Buck AK, Herrmann K, Eckel F, Beer AJ. Pancreatic and hepatobiliary cancers. Methods Mol Biol 2011;727:243-64. [PMID: 21331938 DOI: 10.1007/978-1-61779-062-1_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Hoogenboom TC, Thursz M, Aboagye EO, Sharma R. Functional imaging of hepatocellular carcinoma. Hepat Oncol 2016;3:137-53. [PMID: 30191034 DOI: 10.2217/hep-2015-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
71 Belhocine TZ, Prato FS. Transbilayer phospholipids molecular imaging. EJNMMI Res 2011;1:17. [PMID: 22214386 DOI: 10.1186/2191-219X-1-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
72 Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 2010;73:461-9. [PMID: 20181453 DOI: 10.1016/j.ejrad.2009.12.022] [Cited by in Crossref: 65] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
73 De Gaetano AM, Rufini V, Castaldi P, Gatto AM, Filograna L, Giordano A, Bonomo L. Clinical applications of 18F-FDG PET in the management of hepatobiliary and pancreatic tumors. Abdom Imaging 2012;37:983-1003. [DOI: 10.1007/s00261-012-9845-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
74 Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging 2017;16:1536012117723256. [PMID: 28893116 DOI: 10.1177/1536012117723256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
75 Jadvar H. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: Potential role of other positron emission tomography radiotracers. Semin Nucl Med. 2012;42:247-254. [PMID: 22681673 DOI: 10.1053/j.semnuclmed.2012.02.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]